Best practices for outsourcing, trends and resources
Nucleate and Cromatic
Cromatic is excited to announce our partnership with Nucleate! Nucleate and Cromatic share a mission of supporting the founder-led movement in biotech – we believe the researchers behind the science should be the ones launching the next wave of biotech companies. Cromatic is excited to support new bio-entrepreneurs led companies spinning out of Nucleate by offering access to CRO search and management softwares.
How COVID-19 helped biotech increase diversity in clinical trials
Clinical trials are a crucial part of R&D, but they pose major challenges. Two of the biggest challenges, which will be explored here, are difficulty recruiting participants and lack of participant diversity. As we dive into these issues, we’ll see that the COVID-19 pandemic actually forced changes that help tackle these issues, and these changes can be used going forward!
The Hidden Faces of Operation Warp Speed: How Contract Organizations Accelerated COVID-19 Vaccine Efforts
Contract organizations such as CROs, CMOs, and CDMOs have been crucial in accelerating COVID-19 vaccine development through partnerships with pharmaceutical and biotech companies. In this blog post we examine notable contract organizations that were involved in COVID-19 vaccine development. We also discuss trends contract organizations can play in the future post COVID-19 pandemic.
The rise of the founder-led biotech movement: Part II: Breaking an anti-founder precedent
In contrast to traditional tech, which has a robust history of funding founders, there is a long-standing culture of venture capital (VC)-led biotech. We discuss case studies of VC-led biotech in this article. While the VC-led model of biotech is a proven path to success, one has to wonder what talent may be missed by operating under such defined cultural settings.
How biotech helps reproducibility in biological research
We conjecture that the recent re-emergence of the reproducibility problem in science stems from a growing number of academic work being tested in the biotech sector. The story of suspect data that went on to form the leading theory in Alzheimer’s research is under the spotlight again, and biotech applications can be seen as the impetus for this renewed attention.
A gentle introduction to Techbio
It has become increasingly obvious that computer science innovations are still needed to fuel the biotech industry. Techbio is a general term encompassing any startup serving the biotech industry through hardware and software-based support. Here are some of the major areas of the rapidly growing techbio industry.
Make biology labs greener
Working in a biology lab, it’s difficult for someone to ignore the amount of waste produced in the pursuit of science. But what can be done to make biology labs greener? We discuss some noteworthy initiatives. Biology research is not unique in its use of single-use plastic, but it may be unique in its ability to address the problem.
Lessons from Pixar for biotech founders
Pixar's Braintrust model offers valuable lessons for startup founders. Founders can benefit from forming their own Braintrusts, following Pixar founder Ed Catmull’s guidelines for effective communication around the creative projects that push their companies forward.
Outsourcing as an alternative to traditional technology-transfer structures
The answer to the question, who owns the intellectual property for a biological discovery, has been changing throughout time. The ability to outsource services to CROs paves a new path for scientists to start biotech companies while bypassing traditional tech-transfer structure.
What are CROs and what do they offer?
As the biotechnology sector matures, CROs continue to play key roles in the growth and scale of companies. Indeed, with the breadth of CROs that currently exist, it is possible for a biotech company to exist entirely virtually – solely relying on the different services provided by various CROs to advance their research.
The rise of the founder-led biotech movement (1/3)
Biotech startups face a unique challenge where without a product you can’t raise money, but you need the money to manufacture your product. Luckily, as we see the founder-led movement growing even in biotech, we see more routes that biotech founders can take to be “self-sufficient,” giving up less to outside parties while starting a company.